Advertisement

Topics

AFFiRiS GmbH Company Profile

03:53 EDT 25th September 2017 | BioPortfolio

AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently require a medical solution. The company has established platform technologies and registered the corresponding patent families. The first patents have already been issued. The company employs 35 highly qualified members of staff on 600msquared of rented laboratory facilities at the Campus Vienna Biocenter (http://www.affiris.com).


News Articles [173 Associated News Articles listed on BioPortfolio]

AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board

VIENNA, November 8, 2011 /PRNewswire/ -- Santo VC GmbH has acquired a EUR 20 million stake in Vienna-based AFFiRiS AG effective immediately and has also secured an option for further capit...

Paper describes Affiris' PCSK9 vaccine's efficacy

Affiris' Affitope PD03A well tolerated in Phase I to treat early PD

AFFiRiS AG Announces Top Line Results Of First-In-Human Clinical Study Using AFFITOPE PD03A, Confirming Immunogenicity And Safety Profile In Parkinson's Disease Patients

  Life Sciences Jobs   ...

Stada bündelt Vertriebsgesellschaften in Deutschland

FRANKFURT (Dow Jones)--Der Arzneimittelkonzern Stada bündelt seine Geschäftsaktivitäten in Deutschland. Die bisher vier Vertriebsgesellschaften Stadavita GmbH, Stada GmbH, cell pharm GmbH und Stad....

Original-Research: WILEX AG (von EQUITS GmbH): Kaufen

Original-Research: WILEX AG - von EQUITS GmbH Einstufung von EQUITS GmbH zu WILEX AG Unternehmen: WILEX AG ISIN: DE000A11QVV0 Anlass der Studie: Coverage Aufnahme Empfehlung: Kaufen seit: 19.05.20...

DGAP-News: GBC Kapital GmbH: Erfolgreich abgeschlossene Kapitalmaßnahme der SYGNIS AG - beide Kapitalerhöhungen wurden von der GBC Kapital GmbH und der MC Services AG, jeweils als Co-Lead Manager Institutional Sales, begleitet und waren signifikant

GBC Kapital GmbH: Erfolgreich abgeschlossene Kapitalmaßnahme der SYGNIS AG - beide Kapitalerhöhungen wurden von der GBC Kapital GmbH und der MC Services AG, jeweils als Co-Lead Manager Institution.....

AudioCure Pharma GmbH appoints Dr. Reimar Schlingensiepen as CEO

Dr. Reimar Schlingensiepen succeeds Prof. Hans Rommelspacher, the founder of AudioCure, as CEO Prof. Rommelspacher will continue as CSO AudioCure recently secured funding of about 9 million euros from...

PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity.

Biomechanical Characterization of Subclinical Keratoconus Without Topographic or Tomographic Abnormalities.

To present a case series of patients with subclinical keratoconus with normal topometric (anterior curvature) and tomographic findings in one eye who showed abnormalities detected by Corvis ST (Oculus...

Pulled-out locking screw re-screwed spontaneously in anterior cervical decompression and fusion with the zero-profile implant system: A case report.

The zero-profile, standalone device (Zero-P, Synthes GmbH, Switzerland) has been reported to be an effective and safe treatment method with similar clinical outcomes compared with plate. Instrumental ...

Cyclic and Torsional Fatigue Resistance of Reciprocating Single Files Manufactured by Different Nickel-titanium Alloys.

The aim of this study was to evaluate the cyclic and torsional fatigue resistance of the following reciprocating single-file systems: ProDesign R 25.06 (Easy Equipamentos Odontológicos, Belo Horizont...

Reliability of a Skin Diagnostic Device in Assessing Hydration and Erythema.

To examine the reliability of a skin diagnostic device, the SD202 (Courage+Khazaka GmBH, Cologne, Germany), in assessing hydration and erythema of periwound skin and pressure injury-prone areas.

Clinical Trials [38 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Long-term Safety and Tolerability of AFFITOPE AD01

The purpose of this study is to assess the long-term tolerability and -safety of AFFITOPE AD01 applied during AFFiRiS 001

Long-term Safety and Tolerability of AFFITOPE AD02

The purpose of this study is to evaluate the long-term tolerability and -safety of AFFITOPE AD02 applied during AFFiRiS 002

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

User Performance Evaluation of Contour® Plus One, Accu-Chek® Performa Connect, FreeStyle Optium Neo and OneTouch® Select Plus Blood Glucose Monitoring Systems Following ISO 15197:2013; EN ISO 15197:2015

The user performance evaluation shows whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system. In this study, user performance e...

Companies [523 Associated Companies listed on BioPortfolio]

AFFiRiS GmbH

AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently require a medical solution. The company has established plat...

AFFiRiS AG

On the basis of the company's own patents, AFFiRiS develops tailor-made peptide vaccines against Alzheimer's disease, atherosclerosis, Parkinson's disease hypertension and four other conditions wi...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control ...

Praher Beteiligungs GmbH

The vision of the company founder Ludwig Praher to produce better and better products of high-grade plastics was the basis for sound growth. Under the direction of Ing. Winfried Praher and Ewald Prahe...

More Information about "AFFiRiS GmbH" on BioPortfolio

We have published hundreds of AFFiRiS GmbH news stories on BioPortfolio along with dozens of AFFiRiS GmbH Clinical Trials and PubMed Articles about AFFiRiS GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AFFiRiS GmbH Companies in our database. You can also find out about relevant AFFiRiS GmbH Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record